Life Sciences Health Industry China Briefing - November 2011 (December 6, 2011)
This post was written by Jay Yan, Mao Rong, Zack Dong, Zhao Hong, Gordon Schatz, Dr. David Kan and Katherine Yang.
Reed Smith’s Life Sciences Health Industry China Briefing provides a summary of the monthly news and legal developments relating to China's Pharmaceutical, Medical Device, and Life Sciences/ Health Care Industries.
Some important developments during November include:
- Beijing Hospital Requirements: Overuse of Antibiotics
- SFDA Issues Second Batch of Class II Medical Devices, For Which Distributors Do Not Need to Apply for Medical Devices Distribution License
- Interim Measures on Appraisal of Traditional Chinese Medicine Hospitals: Request for Comments
- Two Pharmaceutical Companies Fined for Monopolizing Compound Reserpine API
- China to Build ADR Monitoring System
- NDRC to Investigate Ex-factory Prices of Drugs
- China Finalizes Healthcare Reform 12th FYP
- China to Launch Massive Survey on TCM Resources
- Notice Concerning Circulation of the 12th Five-year Plan of Biotechnology Development
To read the full briefing by Reed Smith China team members, click here.
